Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+०.२१%
१,०९६.११
+२.३०
+०.२१%
—१,०९३.८११,०९६.५२१,१००.२२१,०९३.२०——
SIXC
Communications
SIXC
Communications
SIXC
+०.४५%
६११.४८
+२.७१
+०.४५%
—६०८.७७६०८.७७६१२.९७६०८.७७——
SIXE
Energy
SIXE
Energy
SIXE
-१.०६%
१,२४१.१७
-१३.३५
-१.०६%
—१,२५४.८११,२५३.०११,२५३.८७१,२२६.३३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.५९%
१,७५०.६९
-१०.४२
-०.५९%
—१,७६१.१११,७६४.२७१,७६६.८८१,७४५.३९——
SIXM
Financials
SIXM
Financials
SIXM
-०.०२%
६४२.४८
-०.१०
-०.०२%
—६४२.५८६४४.८७६४८.४८६४१.४०——
SIXR
Staples
SIXR
Staples
SIXR
-०.१७%
८४९.७२
-१.४१
-०.१७%
—८५१.१३८५५.६६८५८.७५८४५.५६——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.१५%
२१७.६५
-०.३३
-०.१५%
—२१७.९८२१७.९८२१८.६५२१६.८८——
SIXT
Technology
SIXT
Technology
SIXT
+१.७३%
३,२६७.३४
+५५.५१
+१.७३%
—३,२११.८३३,२२७.२१३,२६७.७६३,२२६.५५——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.३८%
९४५.४१
-३.५७
-०.३८%
—९४८.९८९४८.५८९५७.८३९४१.९७——
SIXV
Health care
SIXV
Health care
SIXV
-०.३१%
१,४६९.९१
-४.६१
-०.३१%
—१,४७४.५२१,४७९.०३१,४८१.०४१,४६९.१७——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.५९%
२,४०६.३१
+१४.१९
+०.५९%
—२,३९२.१२२,३९६.९५२,४२१.२२२,३८२.३२——
Q1 2026 earnings • in 3 days
See details
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
US$ ५४.१६
+०.४७%
(+०.२६) 1D
मे १, १५:४०:५६ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMRN...
Open
US$ ५३.९१
High
US$ ५४.२४
Low
US$ ५३.५६
Mkt. cap
१०.४६ अरब
Avg. vol.
१८.३४ लाख
Volume
७.५६ लाख
P/E ratio
३०.०१
52-wk high
US$ ६६.२८
52-wk low
US$ ५०.७६
EPS
US$ १.८०
Beta
०.२९
Shares outstanding
१९.२३ करोड
No. of employees
३ हजार
News stories
From sources across the web
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees३.२२ हजार
Foundedमार्च १९९७
HeadquartersSan Rafael, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitebiomarin.com
Next call ३ दिनमा
मे ४, सोम, १६:३०
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (०.९१ est.)USD
Revenue / Estimate
-/ (७५.१७ करोड est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
७४.५१ करोड
८२.५४ करोड
७७.६१ करोड
८७.४६ करोड
Cost of goods sold
३१.०३ करोड
३१.१४ करोड
५४.९६ करोड
३४.८९ करोड
Cost of revenue
३१.०३ करोड
३१.१४ करोड
५४.९६ करोड
३४.८९ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२०.६१ करोड
२३.२३ करोड
२६.८४ करोड
३२.४२ करोड
Operating expense
२१.१० करोड
२३.७१ करोड
२७.३३ करोड
३२.९० करोड
Total operating expenses
५२.१३ करोड
५४.८५ करोड
८२.२८ करोड
६७.७९ करोड
Operating income
२२.३९ करोड
२७.६९ करोड
-४.६७ करोड
१९.६६ करोड
Other non operating income
-१९.५४ लाख
४८.३३ लाख
५०.९३ लाख
१०.२५ लाख
EBT including unusual items
२३.८१ करोड
२९.७९ करोड
-२.६३ करोड
-२.७२ करोड
EBT excluding unusual items
२३.८१ करोड
२९.७९ करोड
-२.६३ करोड
२१.४१ करोड
Income tax expense
५.२४ करोड
५.७३ करोड
४४.२० लाख
१.९४ करोड
Effective tax rate
२२.०१%
१९.२५%
-१६.७९%
-७१.५२%
Other operating expenses
-
-
-
-
Net income
१८.५७ करोड
२४.०५ करोड
-३.०७ करोड
-४.६६ करोड
Net profit margin
२४.९२%
२९.१४%
-३.९६%
-५.३३%
Earnings per share
१.१३
१.४४
०.१२
०.४६
Interest and investment income
१.९० करोड
१.८८ करोड
१.७९ करोड
१.९२ करोड
Interest expense
-२८.६३ लाख
-२६.७९ लाख
-२५.७९ लाख
-२७.७८ लाख
Net interest expenses
१.६२ करोड
१.६१ करोड
१.५३ करोड
१.६४ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
२४.६० करोड
२९.५४ करोड
-२.८२ करोड
२०.९७ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer